ANET vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Arista Networks, Inc. and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
Arista Networks, Inc. · Technology
$203.47
+15.4% upside to fair value
Med Conviction
Grade C
High Quality
VS
Johnson & Johnson · Healthcare
$270.68
+5.7% upside to fair value
Med Conviction
Grade C
High Quality
QuantHub Verdict
ANET has more upside to fair value
(+15.4%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ANET |
JNJ |
| Current Price |
$203.47 |
$270.68 |
| Fair Value Estimate |
$234.80 |
$286.05 |
| Upside to Fair Value |
+15.4%
|
+5.7%
|
| Market Cap |
$256.2B |
$652.3B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
49.7x
|
20.2x
|
| Price / Sales |
24.3x
|
6.7x
|
| Price / FCF |
49.7x
|
35.3x
|
| Revenue Growth YoY |
+37.7%
|
+6.6%
|
| Gross Margin |
63.0%
|
67.9%
|
| Operating Margin |
43.1%
|
26.8%
|
| Return on Equity |
30.8%
|
25.7%
|
| Dividend Yield |
0% |
1.95% |
| FCF Yield |
2.01%
|
2.83%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Arista Networks designs and sells high-performance Ethernet switching and routing hardware plus its extensible EOS network operating system, and it sits directly in the path of the AI data-center build-out where networking, not compute, is increasingly the bottleneck. The business quality is genuinely high: TTM gross margin of 63.0%, TTM operating margin of 43.1%, TTM net margin of 38.4%, and ROE…
Johnson & Johnson is a 141,700-employee healthcare holding company operating two segments, Innovative Medicine (immunology, oncology, neuroscience, infectious disease, cardiovascular and metabolism, pulmonary hypertension) and MedTech (interventional solutions, orthopaedics, surgery, vision), founded in 1887 and headquartered in New Brunswick, New Jersey. Business quality is high on fundamentals:…
Accumulation Zones
| Metric |
ANET |
JNJ |
| Zone Low |
$176.10 |
$214.54 |
| Zone High |
$199.58 |
$243.14 |
| In Buy Zone? |
No
|
No
|